Compare Equinix Inc (EQIX) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Equinix Inc trades at $1,026.06 (market cap $99.77B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.73 (market cap $58.74B). The key difference: Equinix Inc is the larger of the two by market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold Equinix Inc for 110 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| EQIX | TAK | |
|---|---|---|
Market Cap | $99.77B | $58.74B |
Volume | 480,425 | 3,110,994 |
Sector | Real Estate | Health |
52-Week High | $1.12K | $19.05 |
52-Week Low | $726.09 | $13.23 |
Typical Hold Time | 110 Days | 1 Days |
Enterprise Value | $120.90B | $86.65B |
Dividend Yield | 2.04% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,011.16, down 2.0% on the day amid a bearish technical signal. The stock shows strong fundamentals with revenue growth to $9.22B in 2025 and a net income margin of 15.63%, though valuation ratios like a P/E of 65.07 appear elevated. Recent earnings have been mixed, with Q2 2026 beating expectations but Q1 and Q4 2025 missing. Analyst sentiment remains bullish with a $1,250 consensus price target, supported by strong AI-driven data center demand highlighted in recent news.
The outlook for EQIX is positive due to robust AI infrastructure demand and a solid dividend, but risks include high capital expenditures and debt levels. Investors should weigh growth potential against valuation concerns and execution risks in a competitive sector.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
